# A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission

> **NCT05479058** · PHASE3 · TERMINATED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 22 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Filgotinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05479058
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-26
- **Primary completion:** 2023-10-09
- **Final completion:** 2023-10-09
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** the planned number of participants needed to ensure adequate precision in the estimations and to draw meaningful conclusions was unlikely to be met, questioning the scientific value and ethical grounds for study continuation
- **Last updated:** 2024-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05479058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05479058, "A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05479058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*